<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918619</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-G-H-0804</org_study_id>
    <nct_id>NCT00918619</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection</brief_title>
  <acronym>ESSCALIVER</acronym>
  <official_title>Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-bound Fibrin Sealant During Liver Resection (ESSCALIVER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aesculap AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aesculap AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, patient-blinded, intra-operatively randomised controlled trial. A
      total of 126 patients planned for an elective liver resection will be enrolled in 9 surgical
      centres. The primary objective of this study is to show that the collagen based haemostatic
      device Sangustop® is not inferior to a carrier-bound fibrin sealant (Tachosil®) in achieving
      haemostasis after hepatic resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During liver resection the control of bleeding is a major concern. The liver is predisposed
      to diffuse bleeding because of its extreme vascularity. Locally applicable agents
      (haemostats) are in use in order to achieve control over parenchymatic diffuse bleeding from
      the resection surface and to prevent intraperitoneal complications attributed to bleeding.
      These haemostats include bone wax, gelatine, collagen, oxidized regenerated cellulose, fibrin
      sealant glues, and synthetic glues. A composite product with well documented efficacy is
      Tachosil®. It consists of a collagen fleece carrying the fibrin glue components human
      fibrinogen and human thrombin. It was shown in a RCT to be superior in obtaining
      intraoperative haemostasis over argon beamer in liver resection. A new haemostat product is
      Sangustop®. It is indicated for local haemostasis of capillary bleeding and bleeding of
      parenchymal organs. Sangustop® is composed of native absorbable collagen fibrils without any
      blood serum products or any pharmaceutical activity. The felt structure being rich in surface
      gives a framework for the adhesion of blood platelets, thus provides an additional impetus to
      clotting. The aim of this study is to show that the new microfibrillar collagen hemostat
      Sangustop® is not inferior to the carrier-bound fibrin sealant Tachosil® with regards to
      haemostatic efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with hemostasis 3 minutes after application of the haemostat product</measure>
    <time_frame>3 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to hemostasis</measure>
    <time_frame>10 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Hemostasis</condition>
  <condition>Liver Surgery</condition>
  <arm_group>
    <arm_group_label>Sangustop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tachosil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sangustop</intervention_name>
    <description>Application of Sangustop haemostatic agent on resection area</description>
    <arm_group_label>Sangustop</arm_group_label>
    <other_name>Sangustop®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tachosil</intervention_name>
    <description>Application of Tachosil fibrin sealant on resection area</description>
    <arm_group_label>Tachosil</arm_group_label>
    <other_name>Tachosil®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Age: &gt; 18 years

          -  Gender: male / female

          -  Patients with an indication for liver resection (segmental or non-segmental)

          -  Willing and able to complete the clinical trial procedures, as described in the
             protocol

          -  Signed written informed consent to participate in this clinical trial

        Exclusion:

          -  Presence or sequelae of coagulation disorder, liver cirrhosis, Klatskin tumor

          -  Concurrent participation in another clinical trial with a medical device or medicinal
             product or with interfering endpoints

          -  Concurrent or previous therapy with systemic pharmacologic agents promoting blood
             clotting including but not limited to tranexamix acid, activated factor VII, and
             aprotinine

          -  Known allergy or hypersensitivity to a component of the investigational treatments
             Sangustop® or TachoSil®, to riboflavin or to proteins of bovine origin

          -  Pregnancy or breast feeding

          -  Inability to understand the nature and the extent of the trial and the procedures
             required

          -  Missing signed written informed consent to participate in the study

        Exclusion criteria to be checked during surgery (liver resection):

          -  Resection area estimated by operating surgeon &lt; 16cm2

          -  Infected wound area

          -  Persistant major bleeding after primary haemostasis

          -  No bleeding after resection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolf O. Bechstein, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Frankfurt am Main, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik für Chirurgie, Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe-Universität, Klinik für Allgemein- und Visceralchirurgie</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest, Klinik für Allgemein-, Viszeral- und Minimal Invasive Chirurgie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz, Klinik für Allgemein- und Abdominalchirurgie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern, Ludwig-Maximilians-Universität</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München, Chirurgische Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Moench C, Bechstein WO, Hermanutz V, Hoexter G, Knaebel HP. Comparison of the collagen haemostat Sangustop® versus a carrier-bound fibrin sealant during liver resection; ESSCALIVER-Study. Trials. 2010 Nov 19;11:109. doi: 10.1186/1745-6215-11-109.</citation>
    <PMID>21087530</PMID>
  </reference>
  <results_reference>
    <citation>Moench C, Mihaljevic AL, Hermanutz V, Thasler WE, Suna K, Diener MK, Seehofer D, Mischinger HJ, Jansen-Winkeln B, Knaebel HP, Bechstein WO. Randomized controlled multicenter trial on the effectiveness of the collagen hemostat Sangustop® compared with a carrier-bound fibrin sealant during liver resection (ESSCALIVER study, NCT00918619). Langenbecks Arch Surg. 2014 Aug;399(6):725-33. doi: 10.1007/s00423-014-1203-9. Epub 2014 Jun 1.</citation>
    <PMID>24880345</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>randomized,</keyword>
  <keyword>controlled,</keyword>
  <keyword>haemostatic agents,</keyword>
  <keyword>Sangustop,</keyword>
  <keyword>Tachosil,</keyword>
  <keyword>liver resection,</keyword>
  <keyword>haemostasis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

